<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Janssen-Cilag International NV 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=29704></link><description><![CDATA[Janssen-Cilag International NV 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 16 May 2026 16:01:05 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2017/09/12_3698601005_20170927115325_2181968925.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[European Commission Approves Symtuza® for the Treatment of HIV-1 In Adults and Adolescents in Europe]]></title><link>https://www.newswire.co.kr/newsRead.php?no=857079</link><description><![CDATA[BEERSE, Belgium--(Business Wire/Korea Newswire)--Janssen-Cilag International NV (Janssen) today announced that the European Commission has approved the use of Symtuza® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF])[1], a once-daily darunavir-based single-tablet regimen (STR), for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adoles...]]></description><pubDate>Wed, 27 Sep 2017 13:05:00 +0900</pubDate></item></channel></rss>